EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics

Lisha Ou, Mekedlawit T Setegne, Jeandele Elliot, Fangfang Shen, Laura M K Dassama iD

Chemical Reviews · 26.02.2025 · 125 (4) · 2120-2183

DOI: 10.1021/acs.chemrev.4c00595 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chemical Reviews, online erschienen am 17.01.2025. Verfasst von Lisha Ou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Stanford University, Stanford, California 94305, United States. Hauptthemen laut MEDLINE: Proteins, Proteolysis. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 502 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nascent field of targeted protein degradation (TPD) could revolutionize biomedicine due to the ability of degrader molecules to selectively modulate disease-relevant proteins. A key limitation to the broad application of TPD is its dependence on small-molecule ligands to target proteins of interest. This leaves unstructured proteins or those lacking defined cavities for small-molecule binding out of the scope of many TPD technologies. The use of proteins, peptides, and nucleic acids (otherwise known as "biologics") as the protein-targeting moieties in degraders addresses this limitation. In the following sections, we provide a comprehensive and critical review of studies that have used proteins and peptides to mediate the degradation and hence the functional control of otherwise challenging disease-relevant protein targets. We describe existing platforms for protein/peptide-based ligand identification and the drug delivery systems that might be exploited for the delivery of biologic-based degraders. Throughout the Review, we underscore the successes, challenges, and opportunities of using protein-based degraders as chemical biology tools to spur discoveries, elucidate mechanisms, and act as a new therapeutic modality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteinsProteolysisHumansLigandsAnimalsPeptidesDrug Delivery SystemsSmall Molecule Libraries

Substanzen

ProteinsLigandsPeptidesSmall Molecule Libraries

Autor:innen und Institutionen

  • Department of Chemistry, Stanford University, Stanford, California 94305, United States.
  • Sarafan ChEM-H Institute, Stanford University, Stanford, California 94305, United States.
  • Department of Chemical Engineering, Stanford University, Stanford, California 94305, United States.
  • Department of Microbiology & Immunology, Stanford School of Medicine, Stanford, California 94305, United States.

ORCID-Profile: Laura M K Dassama

Förderung

  • NHLBI NIH HHS
  • NIGMS NIH HHS
  • National Heart, Lung, and Blood Institute
  • Stanford University

Zitieren

APA

Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025). Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. Chemical Reviews, 125(4), 2120-2183. https://doi.org/10.1021/acs.chemrev.4c00595

Vancouver

Ou L, Setegne MT, Elliot J, Shen F, Dassama LMK. Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics. Chemical Reviews. 2025;125(4):2120-2183. doi:10.1021/acs.chemrev.4c00595

BibTeX
@article{Ou2025,
  author = {Ou, Lisha and Setegne, Mekedlawit T and Elliot, Jeandele and Shen, Fangfang and Dassama, Laura M K},
  title = {Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics},
  journal = {Chemical Reviews},
  year = {2025},
  volume = {125},
  number = {4},
  pages = {2120--2183},
  doi = {10.1021/acs.chemrev.4c00595}
}
Kostenlos starten →